Table 3.
Prognostic factors analyzed in articles
| Reference number | 14 | 15 | 16 | 17 | 18 |
|---|---|---|---|---|---|
| OS (%) | 3y (86.3) | 2y (78) | 2y (80.1) | 2y (86) | 2y (88.5) |
| PFS (%) | 3y (85.2) | 2y (67) | 2y (81) | 2y (86) | 2y (80.6) |
| Age (%) | |||||
| Less than or equal to 60 years | 86.7 | 74 | 94.7 | 85.2 | 84.6 |
| Older than 60 years | 13.3 | 26 | 5.3 | 14.8 | 15.4 |
| Sex (%) | |||||
| Male | 56.7 | 63 | 63.2 | 59.3 | 73 |
| Female | 43.3 | 37 | 36.8 | 40.7 | 27 |
| ECOG performance status (%) | |||||
| 0 | 56.7 | 78 | 34.2a | 18.5 | 57.7 |
| 1 | 43.3 | 15 | 63.2 | 66.7 | 38.5 |
| 2 | / | 7 | 2.6 | 14.8 | 3.8 |
| Ann Arbor stage (%) | |||||
| I | 50 | 67 | 52.6a | 66.7 | 76.9 |
| II | 50 | 33 | 28.9 | 33.3 | 23.1 |
| III/IV | / | / | 18.4 | / | / |
| LDH (%) | |||||
| Normal | 80 | 81 | 81.4a | 88.9 | 61.5 |
| Increased | 20 | 19 | 18.6 | 11.1 | 38.5 |
| B symptoms (%) | |||||
| Present | 36.7 | 37 | 57.9a | 37 | 34.6 |
| Absent | 63.3 | 63 | 42.1 | 63 | 65.4 |
| EBV titration (%) | |||||
| At least 64 copies/μL | 36.7a | / | / | / | / |
| Lower than 64 copies/μL | 63.3 | / | / | / | / |
| Regional node (%) | |||||
| Yes | 36.7 | / | 47.4 | 40.7 | / |
| No | 63.3 | / | 52.6 | 59.3 | / |
| IPI scores (%) | |||||
| 0 | 76.7 (0–1) | 59 | 71.1 (0–1)a | 81.5 | 50 |
| 1 | 30 | 18.5 | 42.3 | ||
| 2 | 23.3 | 11 | 18.4 | / | 7.7 |
| 3 | / | / | 5.3 | / | / |
| 4‐5 | / | / | 5.3 | / | / |
| NKIPI scores (%) | |||||
| 0 | / | 26.3a | / | ||
| 1 | 70 (1–2) | 33 | 34.2 | / | 69 (1–2) |
| 2 | 30 | 18.4 | / | ||
| 3 | 30 (3–4) | 26 | 21.1 (3–4) | / | 31 (3–4) |
| 4 | 11 | / | |||
| Platelet count (%) | |||||
| Lower than or equal to 150 000/mm3 | 10a | / | / | / | / |
| Higher than 150 000/mm3 | 90 | / | / | / | / |
| Lymphocyte count (%) | |||||
| Lower than or equal to 1000/mm3 | 23.3a | / | / | / | / |
| Higher than 1000/mm3 | 76.7 | / | / | / | / |
| CRa (%) | 80 | 77 | 81.6 | 74.1 | 80.8 |
| ORR (%) | 83.3 | 81 | 84.2 | 96.3 | 88.5 |
OS, Overall survival; PFS, Progression‐free survival; CR, complete response; ORR, overall response rates; ECOG, Eastern Cooperative Oncology Group; EBV, Epstein–Barr virus; LDH, lactate dehydrogenase; IPI: International Prognostic Index; NKIPI, Korea natural killer/T‐cell lymphoma Prognostic Index.
a
Prognostic factors.